Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon)

重组抗HER2结构域Ⅱ人源化单抗（丽珠集团）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon)

Drug Alias NameLZM-005

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

China Registration ClassClass 1 therapeutic biologic in China

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeN/A